These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 16293849)
1. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment. Kell MR; Power CP BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849 [No Abstract] [Full Text] [Related]
2. HER2 status and benefit from adjuvant trastuzumab in breast cancer. Paik S; Kim C; Wolmark N N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751 [No Abstract] [Full Text] [Related]
3. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. Danese MD; Lalla D; Brammer M; Doan Q; Knopf K Cancer; 2010 Dec; 116(24):5575-83. PubMed ID: 20734398 [TBL] [Abstract][Full Text] [Related]
5. Current perspective - trastuzumab. Hall PS; Cameron DA Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123 [TBL] [Abstract][Full Text] [Related]
6. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer? Seidman AD Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138 [No Abstract] [Full Text] [Related]
7. Trastuzumab in the treatment of breast cancer. Hortobagyi GN N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745 [No Abstract] [Full Text] [Related]
8. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Kulkarni S; Hicks DG Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661 [TBL] [Abstract][Full Text] [Related]
9. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853 [TBL] [Abstract][Full Text] [Related]
10. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995 [TBL] [Abstract][Full Text] [Related]
11. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871 [TBL] [Abstract][Full Text] [Related]
12. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Bult P; Tjan-Heijnen VC; van Krieken H Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274 [No Abstract] [Full Text] [Related]
13. HER-2/neu expression in primary and metastatic breast cancer. Lower EE; Glass E; Blau R; Harman S Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant trastuzumab for HER2-positive early breast cancer. Palmieri FM; Myatt CV; Perez EA Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Piccart-Gebhart MJ Eur J Cancer; 2006 Aug; 42(12):1715-9. PubMed ID: 16806901 [TBL] [Abstract][Full Text] [Related]
16. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
17. Her2 and trastuzumab in breast cancer. Horton J Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040 [No Abstract] [Full Text] [Related]
18. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Jahanzeb M Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510 [TBL] [Abstract][Full Text] [Related]